Overview

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Status:
Completed

Trial end date:
2021-03-16

Target enrollment:

Participant gender:

Summary

This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell ovarian, fallopian tube or primary peritoneal carcinoma patients who have received at least 3 prior lines of chemotherapy and who do not carry deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutations.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborators:

Merck Sharp & Dohme Corp.
Myriad Genetic Laboratories, Inc.

Treatments:

Cediranib
Olaparib